## **AGENDA & MEETING NOTICE**

	Washington State Pharmacy and Therapeutics Committee Date: October 20, 2010 Time: 9:00 a.m. – 4:00 p.m. Location: Marriott Hotel 3201 South 176 <sup>th</sup> Street Seattle, WA 98188	
9:00 a.m. – 9:05 a.m.	Welcome & Introductions	<b>T. Vyn Reese, M.D.</b> P&T Committee Chair
9:05 a.m. – 9:20 a.m.	Selection of new Pharmacy & Therapeutics Committee Chair and Vice Chair	P & T Committee
9:20 a.m. – 10:15 a.m.	Drug Class Review – <b>Update</b> Atypical-Antipsychotics  Stakeholder comments: Limit 3 minutes per person.  P & T Committee discussion and motions	Marian McDonagh OHSU Stakeholders P & T Committee
10:15 a.m. – 10:30 a.m.	Break	All
10:30 a.m. – 11:00 a.m.	Drug Class Review – <b>Update</b> Antihistamines  Stakeholder comments: Limit 3 minutes per person.  P & T Committee discussion and motions	Recorded Presentation OHSU Stakeholders P & T Committee
11:00 a.m. – 11:15 a.m.	Drug Class Review – <b>Scan Oral Hypoglycemics</b> Stakeholder comments: Limit 3 minutes per person.  P & T Committee discussion and motions	T. Vyn Reese, M.D. P&T Committee Chair Stakeholders P & T Committee
11:15 a.m. – 11:30 a.m.	Drug Class Review – <b>Scan Skeletal Muscle Relaxants</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	T. Vyn Reese, M.D. P&T Committee Chair Stakeholders P & T Committee
11:30 a.m. – 11:45 a.m.	Drug Class Review – <b>Scan Triptans</b> Stakeholder comments: Limit 3 minutes per person.  P & T Committee discussion and motions	T. Vyn Reese, M.D. P&T Committee Chair Stakeholders P & T Committee
11:45 a.m. – 12:00 p.m.	Drug Class Review – <b>Scan Alzheimer's</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	T. Vyn Reese, M.D. P&T Committee Chair Stakeholders P & T Committee
12:00 p.m. – 12:30 p.m.	Drug Class Review – <b>Scan Antiplatelets</b> Stakeholder comments: Limit 3 minutes per person.  P & T Committee discussion and motions	T. Vyn Reese, M.D. P&T Committee Chair Stakeholders P & T Committee
12:30 p.m. – 1:30 p.m.	Lunch – On your own	All

## **AGENDA & MEETING NOTICE**

1:30 p.m. – 1:45 p.m.	Drug Utilization Review for Washington  1) Background: Recent FDA action re: Avandia Restrictions  2) Today's Presentation: Roundtable discussion  3) Expected Outcome: DUR guidance to the agencies in light of the FDA's decision.  Stakeholder comments: Limit 3 minutes per person.	Jeff Graham, MD P&T Committee Medical Consultant	
1:45 p.m. – 2:15 p.m.	<ul> <li>Drug Utilization Review for Washington <ol> <li>Background:</li> <li>MPA will implement Generics First for New Starts in AAPs for Adults on November 1, 2010.</li> <li>Today's Presentation:</li> <li>Dr Thompson will present the communication material for Adult AAP "Generics First".</li> <li>Provider - Generic News</li> <li>Client - Generic Myths and truths</li> <li>Pharmacies and EPA codes based on the work group principles</li> </ol> </li> <li>Expected Outcome: <ol> <li>DUR Board approval of ongoing communication plan.</li> </ol> </li> </ul> <li>Stakeholder comments: Limit 3 minutes per person.</li>	Jeff Thompson, MD Chief Medical Officer MPA	
2:15 p.m. – 2:30 p.m.	Break	All	
2:30 p.m. – 4:00 p.m.	Drug Utilization Review for Washington  1) Background: The DUR Board has requested that MPA bring PPIs before the board for a review of drug-drug interactions with this class.  2) Today's Presentation: Nicole Nguyen will present studies and evaluate the quality of evidence in regard to drug-drug interactions with PPIs, with emphasis on clopidogrel.  3) Expected Outcome: The DUR board will provide a recommendation on the appropriateness or changes to existing MPA restrictions for drug-drug interactions with the PPI class.  Stakeholder comments: Limit 3 minutes per person.	Nicole Nguyen, PharmD., MPA Charles Agte, Pharmacy Program Manager, MPA	
4:00 p.m.	Adjourn		
Special notes:	If you are a person with a disability and need a reasonable accommodation or have questions, please call Regina Chacón at (206) 521-2027.		